SEARCH

SEARCH BY CITATION

References

  • Atkins, M.B., Kunkel, L., Sznol, M., and Rosenberg, S.A. (2000). High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6(Suppl. 1), S11S14.
  • Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 61996206.
  • Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596599.
  • Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 25072516.
  • Courtney, K.D., Corcoran, R.B., and Engelman, J.A. (2010). The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 10751083.
  • Davies, M.A. (2011). Regulation, role, and targeting of Akt in cancer. J. Clin. Oncol. 29, 47154717.
  • Davies, M.A., Stemke-Hale, K., Lin, E. et al. (2009). Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 75387546.
  • Eisen, T., Ahmad, T., Flaherty, K.T. et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581586.
  • Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809819.
  • Goel, V.K., Lazar, A.J., Warneke, C.L., Redston, M.S., and Haluska, F.G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154160.
  • Gopal, Y.N., Deng, W., Woodman, S.E., Komurov, K., Ram, P., Smith, P.D., and Davies, M.A. (2010). Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 70, 87368747.
  • Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., Mccusker, J.P., Kluger, Y., and Sznol, M. (2010). PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190200.
  • Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431435.
  • Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209221.
  • Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., and Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 51985202.
  • Hocker, T., and Tsao, H. (2007). Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 28, 578588.
  • Jiang, C.C., Lai, F., Tay, K.H. et al. (2010). Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 1, e69.
  • Jiang, C.C., Lai, F., Thorne, R.F., Yang, F., Liu, H., Hersey, P., and Zhang, X.D. (2011). MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. 17, 721730.
  • Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968972.
  • Karasarides, M., Chiloeches, A., Hayward, R. et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene 23, 62926298.
  • Karbowniczek, M., Cash, T., Cheung, M., Robertson, G.P., Astrinidis, A., and Henske, E.P. (2004). Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 279, 2993029937.
  • Kefford, R.F., Arkenau, H., Brown, M.P., Milward, M., Infante, J.R., Long, G.V., Ouellet, D., Curtis, M., Lebowitz, P.F., and Falchook, G.S. (2010). Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28, 8503.
  • Koul, D., Shen, R., Kim, Y.W., Kondo, Y., Lu, Y., Bankson, J., Ronen, S.M., Kirkpatrick, D.L., Powis, G., and Yung, W.K. (2010). Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro. Oncol. 12, 559569.
  • Lasithiotakis, K.G., Sinnberg, T.W., Schittek, B., Flaherty, K.T., Kulms, D., Maczey, E., Garbe, C., and Meier, F.E. (2008). Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128, 20132023.
  • Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P.P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179193.
  • Montagut, C., Sharma, S.V., Shioda, T. et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 48534861.
  • Nazarian, R., Shi, H., Wang, Q. et al. (2010a). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973977.
  • Nazarian, R., Shi, H., Wang, Q. et al. (2010b). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973977.
  • O’Reilly, K.E., Rojo, F., She, Q.B. et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 15001508.
  • O’Reilly, K.E., Warycha, M., Davies, M.A. et al. (2009). Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin. Cancer Res. 15, 28722878.
  • Paraiso, K.H., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 27502760.
  • Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387390.
  • Shi, H., Kong, X., Ribas, A., and Lo, R.S. (2011). Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 71, 50675074.
  • Sosman, J., Kim, K., Schuchter, L. et al. (2010) Phase II study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAFV600E mutation-positive metastatic melanoma. In Society of Melanoma Research 2010; 7th International Melanoma Congress & 4th Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, (Sydney, Australia).
  • Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., and Kawakami, Y. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 60316039.
  • Tsai, J., Lee, J.T., Wang, W. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 30413046.
  • Tsao, H., Atkins, M.B., and Sober, A.J. (2004). Management of cutaneous melanoma. N. Engl. J. Med. 351, 9981012.
  • Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683695.
  • Wagle, N., Emery, C., Berger, M.F. et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 30863096.
  • Wan, P.T.C., Garnett, M.J., Roe, S.M. et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855867.
  • Xing, F., Persaud, Y., Pratilas, C.A. et al. (2011). Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene doi: 10.1038/onc.2011.250.
  • Yang, H., Higgins, B., Kolinsky, K. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 55185527.